


PHARMACEUTICAL 2021



UNITED THERAPEUTICS Corp Rank 12 of 409





PHARMACEUTICAL 2021





UNITED THERAPEUTICS Corp Rank 12 of 409

The relative strengths and weaknesses of UNITED THERAPEUTICS Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of UNITED THERAPEUTICS Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 287% points. The greatest weakness of UNITED THERAPEUTICS Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 200%, being 554% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 2,167,200 |
| Cost of Goods Sold | 108,100 |
| Intangible Assets | 0 |
| Liabilities, Current | 323,300 |
| Liabilities, Non-Current | 96,500 |
| Other Assets | 1,716,200 |
| Other Compr. Net Income | 0 |
| Other Expenses | 548,000 |
| Other Liabilities | 800,000 |
| Other Net Income | 45,300 |
| Property and Equipment | 731,600 |
| Research and Development | 357,700 |
| Revenues | 1,483,300 |
| Selling, General and Administrative Expense | 0 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 4,615,000 |
| Liabilities | 1,219,800 |
| Expenses | 1,013,800 |
| Stockholders Equity | 3,395,200 |
| Net Income | 514,800 |
| Comprehensive Net Income | 514,800 |
| Economic Capital Ratio | 200% |